Physician profile
Stuart Nathan
NPI 1407836869
$9,704.68
in general payments reported to CMS, 2019-2025
45 companies · $2,375 in 2025
The $2,375 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,899 · 2022: $1,886 · 2023: $1,760 · 2024: $1,784 · 2025: $2,375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,919.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,139.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,499.25 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $850.58 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $687.68 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $596.62 | 2021-2025 | Jardiance, Spiriva Respimat, Glyxambi |
| Bayer Healthcare Pharmaceuticals INC. | $374.08 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $366.91 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $270.11 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $262.28 | 2021-2025 | |
| Amgen INC. | $248.25 | 2022-2025 | Otezla, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $222.13 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $158.89 | 2021-2023 | Xarelto |
| Nestle Healthcare Nutrition INC. | $147.49 | 2021-2022 | |
| Abbott Laboratories | $119.87 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Exact Sciences Corporation | $117.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Nathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.